Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula

A Phase 2 Multicenter, Randomized, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of CBT-004 Ophthalmic Emulsion in Patients With Vascularized Pinguecula

STUDY DESIGN:

Structure:

Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.

Duration of Treatment:

4 weeks of study treatment with 4 weeks follow-up observations.

Control:

Vehicle for CBT-004 (hereafter referred to as Vehicle).

Masking:

Subjects, Investigators, Study Monitors and the Independent Image Reading Center are all masked to the study medications.

Dosage/Dose regimen:

One drop of the assigned study medication will be administered in the study eye TID for 4 weeks. The study eye is defined as the qualified eye (i.e., the eye meeting the inclusion criterion for vascularized pinguecula). If both eyes are qualified, then the eye with the more severe vascularity grade at Visit 1 will be the study eye.

Study Overview

• Status: Recruiting
• Conditions: Pinguecula
• Intervention / Treatment: Drug: CBT-004

• Study Type: Interventional
• Enrollment (Estimated): 75
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Bing Leng, MD; Phone Number: 19493952891; Email: leng_bing@cloudbreaktherapeutics.com
• Study Contact Backup: Name: Van Dinh, MBA; Phone Number: 19493945308; Email: dinh_van@cloudbreaktherapeutics.com

Study Locations

• United States
  • California
    • Glendale, California, United States, 91204
      • Recruiting
      • Global Research Management
      • Contact: Logi El-Harazi

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Pinguecula with a vascularity grade ≥ 3 on a 5-point (0-4) scale.
• Ocular bothersome questionnaire score ≥ 2 on a 5-point (0-4) scale.
• ≥ 18 years of age.
• Able to provide written informed consent and comply with study assessments for the full duration of the study.

Exclusion Criteria:

• Uncontrolled systemic disease, in the opinion of the investigator.
• Active ocular disease other than pinguecula that may confound the study data, including but not limited to severe dry eye disease, pterygium, uncontrolled blepharitis, anterior membrane dystrophy, Salzmann's, glaucoma, or active ocular infection.
• History of ocular herpes disease, iritis/uveitis, in either eye.
• Any ocular surgical procedure within the last 3 months or anticipated ocular surgery during the study, in either eye.
• Anticipated wearing of contact lenses during any portion of the study. Patients, who wear soft contact lenses should discontinue wearing them at least 7 days prior to Day 1 visit. Patients wearing rigid gas permeable or hard contact lenses should discontinue wearing them at least 3 weeks prior to Day 1 visit.
• Female patients who are pregnant, nursing, or planning a pregnancy during the study.
• Current enrollment in an investigational drug or device study or participation in such a study within 30 days prior to entry into this study.
• History of myocardial infarction or stroke.
• Any condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study.
• Known allergy or sensitivity to the study medication(s) or its components.
• Current or anticipated use of topical ophthalmic medications in the study eye. Patients must have discontinued use of ophthalmic medications in the study eye for at least 2 weeks (4 weeks for Restasis® or Xiidra®) prior to Day 1 visit. Artificial tears are allowed in the study eye until 7 days prior to Visit 1 and should not be used during the treatment phase of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: CBT-004	Drug: CBT-004; Dose response study
Experimental: 0.05% CBT-004	Drug: CBT-004; Dose response study
Experimental: 0.075% CBT-004	Drug: CBT-004; Dose response study

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change from Baseline in conjunctival hyperemia grade at Day 28 (Week 4).	1 month

Secondary Outcome Measures

Outcome Measure	Time Frame
Change from Baseline conjunctival hyperemia digital image grade at Days 7 (Week 1) and 56 (Week 8).	2 month

Collaborators and Investigators

• Sponsor: Cloudbreak Therapeutics, LLC

Study record dates

Study Major Dates

• Study Start (Actual): December 21, 2023
• Primary Completion (Estimated): August 1, 2025
• Study Completion (Estimated): October 1, 2025

Study Registration Dates

• First Submitted: May 5, 2021
• First Submitted That Met QC Criteria: May 7, 2021
• First Posted (Actual): May 12, 2021

Study Record Updates

• Last Update Posted (Actual): January 29, 2024
• Last Update Submitted That Met QC Criteria: January 25, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Conjunctival Diseases; Pinguecula
• Other Study ID Numbers: CBT-CS103

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No